Equities research analysts expect Bristol-Myers Squibb Co (NYSE:BMY) to announce earnings of $1.47 per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Bristol-Myers Squibb’s earnings, with estimates ranging from $1.42 to $1.51. Bristol-Myers Squibb posted earnings per share of $1.18 in the same quarter last year, which suggests a positive year over year growth rate of 24.6%. The company is scheduled to announce its next quarterly earnings report on Thursday, July 23rd.
On average, analysts expect that Bristol-Myers Squibb will report full year earnings of $6.14 per share for the current year, with EPS estimates ranging from $6.08 to $6.20. For the next year, analysts anticipate that the company will post earnings of $7.35 per share, with EPS estimates ranging from $7.28 to $7.40. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Bristol-Myers Squibb.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.23. Bristol-Myers Squibb had a return on equity of 30.06% and a net margin of 3.08%. The business had revenue of $10.78 billion for the quarter, compared to analyst estimates of $10.04 billion. During the same period in the previous year, the company earned $1.10 earnings per share. The company’s revenue for the quarter was up 82.1% compared to the same quarter last year.
In other news, EVP Louis S. Schmukler sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $62.68, for a total transaction of $1,567,000.00. Following the completion of the transaction, the executive vice president now directly owns 26,777 shares in the company, valued at $1,678,382.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP John E. Elicker sold 15,805 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $61.01, for a total value of $964,263.05. Following the transaction, the executive vice president now owns 58,666 shares of the company’s stock, valued at $3,579,212.66. The disclosure for this sale can be found here. Insiders own 0.14% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Anderson Fisher LLC raised its holdings in Bristol-Myers Squibb by 1.7% during the fourth quarter. Anderson Fisher LLC now owns 24,792 shares of the biopharmaceutical company’s stock worth $1,591,000 after purchasing an additional 417 shares in the last quarter. Earnest Partners LLC raised its holdings in Bristol-Myers Squibb by 45.4% during the fourth quarter. Earnest Partners LLC now owns 1,147 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 358 shares in the last quarter. Becker Capital Management Inc. bought a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $220,000. Benin Management CORP raised its holdings in Bristol-Myers Squibb by 35.4% during the fourth quarter. Benin Management CORP now owns 11,868 shares of the biopharmaceutical company’s stock worth $762,000 after purchasing an additional 3,100 shares in the last quarter. Finally, Financial Counselors Inc. raised its holdings in Bristol-Myers Squibb by 9.0% during the fourth quarter. Financial Counselors Inc. now owns 168,235 shares of the biopharmaceutical company’s stock worth $10,799,000 after purchasing an additional 13,916 shares in the last quarter. 76.51% of the stock is currently owned by hedge funds and other institutional investors.
Bristol-Myers Squibb stock traded down $0.35 during midday trading on Monday, hitting $60.79. The stock had a trading volume of 9,226,185 shares, compared to its average volume of 16,080,694. The company has a current ratio of 1.66, a quick ratio of 1.51 and a debt-to-equity ratio of 0.86. The stock has a market cap of $138.34 billion, a P/E ratio of 75.05, a P/E/G ratio of 1.18 and a beta of 0.74. Bristol-Myers Squibb has a 12 month low of $42.48 and a 12 month high of $68.34. The business has a fifty day moving average price of $60.48 and a 200 day moving average price of $60.71.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Friday, April 3rd were given a dividend of $0.45 per share. The ex-dividend date was Thursday, April 2nd. This represents a $1.80 annualized dividend and a dividend yield of 2.96%. Bristol-Myers Squibb’s dividend payout ratio is presently 38.38%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.